Pharvaris N.V. - (PHVS) closed at $33.36 on November 13, 2026, down 1.4% from the previous close, on volume of 178,544 shares (30-day average 607,819).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
RBC Capital Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks (Sat, 14-Nov 12:45 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 13-Nov 9:31 AM ET)
TipRanks (Fri, 13-Nov 9:10 AM ET)
Wedbush Sticks to Their Buy Rating for Pharvaris (PHVS)
TipRanks (Fri, 13-Nov 8:55 AM ET)
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Globe Newswire (Thu, 12-Nov 10:28 AM ET)
Pharvaris Reports Third-Quarter 2026 Results and Business Update
TipRanks (Thu, 12-Nov 8:08 AM ET)
Seeking Alpha News (Thu, 12-Nov 6:51 AM ET)
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 6:50 AM ET)
TipRanks (Mon, 9-Nov 8:40 AM ET)
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Globe Newswire (Thu, 29-Oct 6:50 AM ET)
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Pharvaris N.V. - trades on the NASDAQ stock market under the symbol PHVS.
As of November 13, 2026, PHVS stock price declined to $33.36 with 178,544 million shares trading.
PHVS has a beta of 0.34, meaning it tends to be less sensitive to market movements. PHVS has a correlation of 0.01 to the broad based SPY ETF.
PHVS has a market cap of $2.33 billion. This is considered a Mid Cap stock.
In the last 3 years, PHVS traded as high as $43.25 and as low as $11.51.
The top ETF exchange traded funds that PHVS belongs to (by Net Assets): IBB, IEFA, SCZ, EWN, ONEQ.
PHVS has outperformed the market in the last year with a price return of +29.3% while the SPY ETF gained +11.5%. However, in the short term, PHVS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.5% vs -2.1% return in SPY. But in the last 2 weeks, PHVS shares have fared better than the market returning -0.7% compared to SPY -1.9%.
PHVS support price is $32.69 and resistance is $34.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHVS shares will trade within this expected range on the day.